FDA Revises Celexa Warnings Over Heart Disorder Risk

Law360, New York (March 28, 2012, 4:20 PM EDT) -- Months after warning that high doses of Forest Laboratories Inc.'s antidepressant Celexa could cause a potentially fatal irregular heartbeat, the U.S. Food and Drug Administration announced Wednesday that it had revised its recommendations to clarify how at-risk patients could still benefit from the drug.

The citalopram drug's updated dosing and warning recommendations stem from the FDA's warning in August that taking more than 40 milligrams of Celexa each day can cause changes in the electrical activity of the heart, prolonging the QT interval — the interval...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.